A Multicenter, Single-arm, Observational Study Describing the Clinical Benefits of Bevacizumab (Avastin) Treatment in Patients With Metastatic Breast Cancer (AVAREG Study)
Latest Information Update: 07 Nov 2021
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms AVAREG
- Sponsors Roche
- 21 Sep 2020 Results of pooled analysis from four studies (B-SHARE, ML21647, ML21165 and ML22452) presented at the 45th European Society for Medical Oncology Congress.
- 11 Oct 2016 Results (n=2135) of a pooled analysis from ML21165, AVANTI and AVAREG studies assessing real-world effectiveness and safety in clinically important subgroups, presented at the 41st European Society for Medical Oncology Congress.
- 04 Feb 2013 New trial record